BBLG Stock Forecast: Bone Biologics Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.27
−2.36% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 37 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$932,329.00
Ticker Nerd rank
37/ 100
Median analyst target
$12
Analysts covering
—
Revenue$0.0
Operating income−$808K
Net income−$774K
Free cash flow−$518K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.4%
1M
−37.6%
YTD
−81.5%
1Y
−81.1%
From 52W high
−87.3%
From 52W low
0.0%
$0.27
$2.11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Bone Biologics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
37/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
81
Growth
69
Accruals
50
Volatility
32
Issuance
31
Quality
26
Value
3
Momentum
3

Revisions (81): Analysts have, on balance, been raising their forecasts.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BBLG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BBLG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26BBLGHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Apr 2023EF HuttonReiteratesBuy$2.25
3 Apr 2023EF HuttonReiteratesBuy$2.25
18 Oct 2022EF HuttonInitiatesBuy$2.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BBLG appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BBLG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Bone Biologics Corp. returned −81.1% against +6.9% for the S&P 500, dividends included.

BBLG vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26BBLGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BBLG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.2×

Cheaper than 95% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−47.5%

Higher than 22% of US stocks

Return on assets
−29.5%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bone Biologics Corp. has a market value of $932K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$2.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$2.6M.

  • Shares outstanding: 1.8M.

  • Bone Biologics Corp. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

BBLG and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BBLGBone Biologics Corp.$932,329.0037
KPTIKaryopharm Therapeutics, Inc.$901,700.00—
MTNBMatinas BioPharma Holdings, Inc.$890,700.0039
GOVXGeoVax Labs, Inc.$985,500.0031
SLXNSilexion Therapeutics Corp.$830,400.0028
LNAILunai Bioworks, Inc.$829,700.00—
VBIOValion Bio, Inc.$1.0M2

Take a look at BBLG’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Bone Biologics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BBLG

How does Ticker Nerd's model rank BBLG?

As at 21 Nov 2026, Bone Biologics Corp. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (81 of 100).

What is the BBLG stock forecast for 2030?

No analyst covering Bone Biologics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBLG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has BBLG stock performed over the past year?

Bone Biologics Corp. returned -81.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bone Biologics Corp. do?

Bone Biologics Corp is a clinical-stage medical device company focused on orthobiologic products for spinal fusion and bone regeneration. The company’s current work centers on NELL-1, a recombinant human protein used with demineralized bone matrix to support targeted bone healing in lumbar spinal fusion procedures.

Company

About Bone Biologics Corp.

Bone Biologics Corp is a clinical-stage medical device company focused on orthobiologic products for spinal fusion and bone regeneration. The company’s current work centers on NELL-1, a recombinant human protein used with demineralized bone matrix to support targeted bone healing in lumbar spinal fusion procedures. Its product development is aimed at improving outcomes in skeletal repair, with applications that extend across spinal, orthopedic, reconstructive, neurosurgical, and sports medicine settings. Bone Biologics Corp operates in the healthcare technology and medical specialties space, where orthobiologics play an important role in supporting bone growth and repair during surgery. Headquartered in Burlington, Massachusetts, Bone Biologics Corp is positioned as a developer of regenerative solutions for surgeons and medical centers working with complex bone-related procedures.

CEO Mr. Jeffrey Frelick · 2 employees · United States · https://www.bonebiologics.com